Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Treasury Shares (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Treasury Shares for 4 consecutive years, with $2.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Treasury Shares rose 655.3% to $2.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.4 million, a 655.3% increase, with the full-year FY2024 number at $256490.0, up 687.79% from a year prior.
  • Treasury Shares was $2.4 million for Q3 2025 at Whitehawk Therapeutics, roughly flat from $2.4 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $2.4 million in Q2 2025 to a low of $32558.0 in Q4 2023.
  • A 3-year average of $779755.6 and a median of $325628.0 in 2024 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: skyrocketed 687.79% in 2024, then plummeted 52.61% in 2025.
  • Whitehawk Therapeutics' Treasury Shares stood at $32558.0 in 2023, then surged by 687.79% to $256490.0 in 2024, then soared by 834.69% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Treasury Shares are $2.4 million (Q3 2025), $2.4 million (Q2 2025), and $161721.0 (Q1 2025).